In animal models, adrenaline acts as an inoconstrictor, dobutamine as an inodilator, and milrinone predominantly as a vasodilator with weak inotropic effects.
Answers are grounded in this paper and cite their sources.
Caution against direct clinical translation of these agent-specific effects; leaves open the need for human trials to guide inotrope selection.
This study evaluated the effects of milrinone, adrenaline and dobutamine with pressure-volume loops and isolated atrial tissue. Agonist dose-response curves to incremental drug infusions were acquired in 11 anesthetised rabbits using pressure-volume loops and preload recruitable stroke work indicated contractility. Agonist concentration-response curves were completed in eight guinea pig isolated atria, for effects on atrial rate and force. Adrenaline and dobutamine increased contractility (P = 0.006 and 0.044), whereas milrinone did not (P = 0.895). Only adrenaline increased myocardial stiffness (P < 0.001). Milrinone decreased vascular resistance (P < 0.001) and elicited the greatest fall in mean arterial pressure (P < 0.001) and increased ejection fraction (P < 0.001). Adrenaline decreased heart rate (P < 0.001), whereas dobutamine and milrinone increased it (P = 0.006 and 0.011). Milrinone increased the force of left atrial contraction, but its inotropic effect was weak and significantly less than with dobutamine and adrenaline (P < 0.001). Adrenaline acted as an inoconstrictor, dobutamine an inodilator and milrinone predominantly a vasodilator
No takes yet. Share an insight, caveat, or question.
Royse et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: